Chen Zhaohui, Hu Junyi, Liu Lilong, Zhang Youpeng, Liu Dandan, Xiong Ming, Zhao Yi, Chen Ke, Wang Yu-Mei
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Infect Dis Ther. 2021 Mar;10(1):421-438. doi: 10.1007/s40121-020-00379-2. Epub 2021 Jan 22.
This retrospective, single-center study was performed to systemically describe the characteristics and outcomes of patients with severe and critical coronavirus disease 2019 (COVID-19) in Wuhan, analyze the risk factors, and propose suggestions for clinical diagnosis and treatment to guide the subsequent clinical practice.
A total of 753 consecutive patients with COVID-19 admitted to the West Campus of Wuhan Union Hospital from January 22, 2020 to May 7, 2020 were enrolled in this study. Demographic, clinical, laboratory, and outcome data were extracted from the electronic medical records of Wuhan Union Hospital and were exhaustively analyzed using R (version 3.6.1).
A total of 493 severe and 228 critical cases out of 753 COVID-19 cases were considered in this study. Among the critical cases, the death rate was 79.4%, and age was a risk factor for death. Compared to the severe disease group, the critical disease group had higher white blood cell (WBC) and neutrophil counts and a decreased lymphocyte count at admission. Compared to early death cases (death within 1 week after admission), a more prolonged course of the disease was associated with a higher risk of hypoproteinemia, liver injury, thrombocytopenia, anemia, disseminated intravascular coagulation (DIC), coagulation disorders, acute kidney injury (AKI), and infection. Higher creatine kinase (CK) and lactate dehydrogenase (LDH) levels were related to early death events, but univariate and multivariate analyses confirmed only LDH as an independent predictor of early death. Notably, anticoagulation therapy was associated with an improved prognosis of critical cases in this cohort.
Our results showed large differences between patients with severe and critical COVID-19. During the course of COVID-19 in the critical disease group, the incidence of hypoproteinemia, anemia, thrombocytopenia, and coagulation disorders increased significantly, which highlighted the importance of medical care in the first week after admission. LDH could act as an independent predictor of early death in critical cases, and anticoagulation therapy was correlated with an improved prognosis of patients with critical COVID-19.
本项回顾性单中心研究旨在系统描述武汉地区新型冠状病毒肺炎(COVID-19)重型及危重型患者的特征与预后,分析危险因素,并为临床诊断与治疗提出建议,以指导后续临床实践。
本研究纳入了2020年1月22日至2020年5月7日连续收治于武汉协和医院西院区的753例COVID-19患者。从武汉协和医院的电子病历中提取人口统计学、临床、实验室及预后数据,并使用R软件(版本3.6.1)进行详尽分析。
本研究共纳入753例COVID-19病例中的493例重型和228例危重型病例。危重型病例的死亡率为79.4%,年龄是死亡的危险因素。与重型疾病组相比,危重型疾病组入院时白细胞(WBC)和中性粒细胞计数更高,淋巴细胞计数降低。与早期死亡病例(入院后1周内死亡)相比,病程延长与低蛋白血症、肝损伤、血小板减少、贫血、弥散性血管内凝血(DIC)、凝血功能障碍、急性肾损伤(AKI)及感染的风险更高相关。肌酸激酶(CK)和乳酸脱氢酶(LDH)水平升高与早期死亡事件相关,但单因素和多因素分析仅证实LDH是早期死亡的独立预测因素。值得注意的是,抗凝治疗与该队列中危重型病例的预后改善相关。
我们的结果显示COVID-19重型和危重型患者之间存在较大差异。在危重型疾病组的COVID-19病程中,低蛋白血症、贫血、血小板减少及凝血功能障碍的发生率显著增加,这凸显了入院后第一周医疗护理的重要性。LDH可作为危重型病例早期死亡的独立预测因素,抗凝治疗与COVID-19危重型患者的预后改善相关。